FORXIGA 10 MG — DIN 02435470
DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) : 10 MG · ASTRAZENECA CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is FORXIGA?
FORXIGA 10 MG contains DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02435470, held by ASTRAZENECA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Jan-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FORXIGA used for?
Adjunct to diet/exercise for T2DM; reduce risk of hospitalization for heart failure in T2DM; treatment of heart failure (CV death/hospitalization reduction); treatment of chronic kidney disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Dapagliflozin cost around the world?
Dapagliflozin is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 40 | USD███.██ |
| Saudi Arabia | public | 19 | 38 | SAR███.██ |
| South Africa | single exit price | 31 | 31 | ZAR███.██ |
| Bahrain | retail (max) | 14 | 26 | BHD███.██ |
| Australia | ex-manufacturer | 5 | 16 | AUD███.██ |
| Greece | producer price (ex-factory) | 9 | 9 | EUR███.██ |
| Iceland | max wholesale | 2 | 5 | ISK███.██ |
| Czechia | max producer price (ex-factory) | 1 | 4 | CZK███.██ |
| Luxembourg | reimbursement | 3 | 3 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 2 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
| Romania | max producer price | 1 | 2 | RON███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
179 pack listings across 91 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Dapagliflozin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Dapagliflozin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
18 holders have a Canadian DIN containing Dapagliflozin, across 36 DINs, of which 26 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCEL PHARMA INC | 2 | 2 | ACCEL-DAPAGLIFLOZIN | Sourceable in Canada |
| ANGITA PHARMA INC. | 2 | 2 | AG-DAPAGLIFLOZIN | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO-DAPAGLIFLOZIN | Sourceable in Canada |
| ASTRAZENECA CANADA INC | 2 | 2 | FORXIGA | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-DAPAGLIFLOZIN | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 2 | 2 | GLN-DAPAGLIFLOZIN | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP DAPAGLIFLOZIN | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 2 | RIVA-DAPAGLIFLOZIN | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-DAPAGLIFLOZIN | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 2 | PMS-DAPAGLIFLOZIN | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 2 | PRO-DAPAGLIFLOZIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 2 | SANDOZ DAPAGLIFLOZIN | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Blisters in cartons of 30 tablets. |
| Storage | Not explicitly detailed in provided text (standard section 11 mentioned in TOC but text cuts off). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Dapagliflozin |
|---|---|
| ATC code | A10BK01 |
| AHFS class | 68:20.18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02435470 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2435470 |
| Brand name | FORXIGA |
| Generic / active ingredient | DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) : 10 MG |
| Market authorization holder | ASTRAZENECA CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | A10BK01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BK |
| Current status | MARKETED |
| Status date | 16-Jan-2015 |
| Original market date | 2015-01-16 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
T2DM: Starting dose 5 mg once daily, may increase to 10 mg. Heart Failure and CKD: 10 mg once daily. Take orally at any time with or without food. Interrupt 3 days prior to major surgery.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or any ingredients; patients on dialysis.
Warnings and precautions
Serious risk of Diabetic Ketoacidosis (DKA); risk of volume depletion, hypotension, acute kidney injury, and necrotizing fasciitis of the perineum (Fournier’s gangrene).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
26 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-DAPAGLIFLOZIN | 10 MG | TABLET | ACCEL PHARMA INC | MARKETED | 02543192 |
| ACCEL-DAPAGLIFLOZIN | 5 MG | TABLET | ACCEL PHARMA INC | MARKETED | 02543184 |
| AG-DAPAGLIFLOZIN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02533057 |
| AG-DAPAGLIFLOZIN | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02533049 |
| APO-DAPAGLIFLOZIN | 5 MG | TABLET | APOTEX INC | MARKETED | 02527189 |
| APO-DAPAGLIFLOZIN | 10 MG | TABLET | APOTEX INC | MARKETED | 02527197 |
| AURO-DAPAGLIFLOZIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | 02531410 |
| AURO-DAPAGLIFLOZIN | 5 MG | TABLET | AURO PHARMA INC | MARKETED | 02531402 |
| FORXIGA | 5 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | 02435462 |
| GLN-DAPAGLIFLOZIN | 10 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02519860 |
2 · Same class — other molecules in ATC A10BK
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dapagliflozin | ACCEL-DAPAGLIFLOZIN · AG-DAPAGLIFLOZIN · APO-DAPAGLIFLOZIN · AURO-DAPAGLIFLOZIN · +14 more | 36 | 26 | Yes |
| Canagliflozin | INVOKANA | 2 | 2 | Yes |
| Empagliflozin | JARDIANCE | 2 | 2 | Yes |
| Ertugliflozin | STEGLATRO | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · +1 more | 112 | 23 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is FORXIGA called?
The same molecule, Dapagliflozin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dapazin | Latin | Bahrain, Saudi Arabia |
| Depaxamet | Latin | Saudi Arabia |
| Gripdi | Latin | Bahrain, Saudi Arabia |
| Metflozin XR | Latin | Saudi Arabia |
| XIGDUO XR | Latin | Bahrain |
| DAFASGLIT | Latin | Bahrain |
| Daglozin | Latin | Saudi Arabia |
| Dapagliflozin Evapharma | Latin | Saudi Arabia |
| DAPAGLIFLOZIN-EVAPHARMA | Latin | Bahrain |
| Dapagloz | Latin | Saudi Arabia |
| Dapinzo | Latin | Saudi Arabia |
| Dapxiga | Latin | Saudi Arabia |
| Depaxa | Latin | Saudi Arabia |
| Dezeroga | Latin | Bahrain, Saudi Arabia |
| Dezeroga-Met | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.